Therapeutic Development

The Veiseh and Tabor groups are collaborating to develop a pulmonary therapeutic design is to prevent pathogenic bacteria from causing infections in the lungs of COVID-19 patients, which his linked to poor clinical outcomes.

Researchers in the Department of Bioengineering, in collaboration with the Department of Biosciences, are initiating studies on the fundamental mechanisms by which the SARS-Cov-2 interacts with and enters cell membranes. These studies build on our expertise in membrane biophysics, membrane biochemistry, cell signalling and cellular imaging. We have already generated ideas for novel drug targets and welcome collaborations with other researchers to accelerate this effort.